Featured Research

from universities, journals, and other organizations

Gene may help predict best chemotherapy treatment for pancreatic cancer patients

Date:
February 5, 2013
Source:
Moffitt Cancer Center
Summary:
Researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States. The scientists conducted a study that better defines the role of ribonucleotide reductase M1 (RRM1). The RRM1 gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine, a commonly used chemotherapy in pancreatic cancer.

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States. Researcher Richard Kim, M.D., assistant member of the Experimental Therapeutics Program and colleagues from several other research institutions conducted a study that better defines the role of ribonucleotide reductase M1 (RRM1). The RRM1 gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine, a commonly used chemotherapy in pancreatic cancer.

In the study, which appeared in the Jan. 1 issue of Cancer, the research team investigated the therapeutic predictive value of RRM1 expression for the chemotherapy drug gemcitabine. They found that for patients with pancreatic adenocarcinoma removed by surgery, low RRM1 expression predicted an overall survival benefit with gemcitabine therapy. High RRM1 expression predicted benefit from non-gemcitabine therapy.

"We previously hypothesized that low expression of RRM1 could predict the treatment success of gemcitabine," Kim said. "This study was carried out to determine whether RRM1 expression correlates with better survival for patients receiving gemcitabine therapy."

The retrospective study included 122 patients who had undergone surgery for pancreatic adenocarcinoma from 1999 to 2007. In the subgroup of patients who received gemcitabine therapy, those with low RRM1 expression had longer overall survival and a trend toward progression-free survival. Those patients with high RRMI expression who received non-gemcitabine therapy had significantly longer overall survival and progression-free survival.

"Our findings indicate that to achieve the best survival after surgical resection, the level of RRM1 expression may be used to select which patients receive gemcitabine therapy and which do not," Kim said.

The authors noted that their findings were consistent with similar studies on the role RRM1 plays in chemotherapy for patients with non-small cell lung cancer, yet their conclusions "should be interpreted with caution" due to their small sample size and the therapeutic success of non-gemcitabine therapies after surgery.

"A validation study should be carried out before the current findings can be clinically applied," Kim added.

Kim worked with researchers from Cleveland Clinic, Case Western Reserve University School of Medicine, Veridex, LLC, and Johnson & Johnson Company on this study.


Story Source:

The above story is based on materials provided by Moffitt Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hao Xie, Wei Jiang, John Jiang, Yixin Wang, Richard Kim, Xiaobo Liu, Xiuli Liu. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 2013; 119 (1): 173 DOI: 10.1002/cncr.27715

Cite This Page:

Moffitt Cancer Center. "Gene may help predict best chemotherapy treatment for pancreatic cancer patients." ScienceDaily. ScienceDaily, 5 February 2013. <www.sciencedaily.com/releases/2013/02/130205123437.htm>.
Moffitt Cancer Center. (2013, February 5). Gene may help predict best chemotherapy treatment for pancreatic cancer patients. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/02/130205123437.htm
Moffitt Cancer Center. "Gene may help predict best chemotherapy treatment for pancreatic cancer patients." ScienceDaily. www.sciencedaily.com/releases/2013/02/130205123437.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins